Heather L. Sings

12.8k total citations · 2 hit papers
59 papers, 5.8k citations indexed

About

Heather L. Sings is a scholar working on Epidemiology, Surgery and Microbiology. According to data from OpenAlex, Heather L. Sings has authored 59 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Epidemiology, 20 papers in Surgery and 11 papers in Microbiology. Recurrent topics in Heather L. Sings's work include Cervical Cancer and HPV Research (27 papers), Hepatitis B Virus Studies (21 papers) and Pneumonia and Respiratory Infections (18 papers). Heather L. Sings is often cited by papers focused on Cervical Cancer and HPV Research (27 papers), Hepatitis B Virus Studies (21 papers) and Pneumonia and Respiratory Infections (18 papers). Heather L. Sings collaborates with scholars based in United States, Canada and France. Heather L. Sings's co-authors include Eliav Barr, Suzanne M. Garland, Richard M. Haupt, Radha Railkar, Marc Steben, Daron G. Ferris, Gonzalo Pérez, Margaret Burroughs, Clifford A. Brass and Fred Poordad and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Heather L. Sings

59 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

2007 1.4k citations Suzanne M. Garland, Mauricio Hernández‐Ávila et al. New England Journal of Medicine profile →
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

2011 1.2k citations Bruce R. Bacon, Stuart C. Gordon et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heather L. Sings United States	34	4.8k	1.5k	1.5k	587	522	59	5.8k
Eliav Barr United States	43	7.6k 1.6×	2.9k 2.0×	1.9k 1.3×	680 1.2×	1.1k 2.1×	75	10.4k
Mireia Díaz Spain	25	6.9k 1.4×	2.9k 2.0×	1.5k 1.0×	832 1.4×	1.4k 2.8×	43	9.2k
Laurent Bélec France	41	2.2k 0.5×	269 0.2×	303 0.2×	821 1.4×	576 1.1×	262	5.7k
Shinichi Oka Japan	45	2.8k 0.6×	587 0.4×	678 0.5×	187 0.3×	1.0k 2.0×	475	8.1k
Karl R. Beutner United States	33	3.2k 0.7×	809 0.5×	151 0.1×	260 0.4×	738 1.4×	80	7.4k
Philippe Halfon France	48	4.7k 1.0×	475 0.3×	4.1k 2.8×	132 0.2×	783 1.5×	223	7.8k
Debra L. Hanson United States	42	3.3k 0.7×	351 0.2×	408 0.3×	320 0.5×	155 0.3×	105	6.2k
Daniel Shouval Israel	48	6.1k 1.3×	611 0.4×	5.9k 4.1×	55 0.1×	772 1.5×	225	8.8k
Michael Robertson United States	38	3.3k 0.7×	302 0.2×	2.2k 1.5×	148 0.3×	1.0k 2.0×	137	6.4k
Maria Lina Tornesello Italy	45	1.8k 0.4×	770 0.5×	350 0.2×	415 0.7×	2.2k 4.2×	184	5.9k

Countries citing papers authored by Heather L. Sings

Since Specialization

Citations

This map shows the geographic impact of Heather L. Sings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather L. Sings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather L. Sings more than expected).

Fields of papers citing papers by Heather L. Sings

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather L. Sings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather L. Sings. The network helps show where Heather L. Sings may publish in the future.

Co-authorship network of co-authors of Heather L. Sings

This figure shows the co-authorship network connecting the top 25 collaborators of Heather L. Sings. A scholar is included among the top collaborators of Heather L. Sings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather L. Sings. Heather L. Sings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilson, Michele, Matt Wasserman, Maarten J. Postma, et al.. (2018). Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. Infectious Diseases and Therapy. 7(3). 353–371. 22 indexed citations

Sings, Heather L.. (2017). Pneumococcal conjugate vaccine use in adults – Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine. 35(40). 5406–5417. 23 indexed citations

Istúriz, Raúl, Beate Schmöele-Thoma, Daniel A. Scott, et al.. (2015). Pneumococcal conjugate vaccine use in adults. Expert Review of Vaccines. 15(3). 279–293. 15 indexed citations

Ruiz-Sternberg, Ángela María, Tiina Eriksson, Matti Lehtinen, et al.. (2012). Proximity of First Sexual Intercourse to Menarche and Risk of High-Grade Cervical Disease. The Journal of Infectious Diseases. 206(12). 1887–1896. 13 indexed citations

Sulkowski, Mark S., Fred Poordad, M.P. Manns, et al.. (2012). Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 57(3). 974–984. 52 indexed citations

Flamm, Steven L., Eric Lawitz, Ira M. Jacobson, et al.. (2012). Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. Clinical Gastroenterology and Hepatology. 11(1). 81–87.e4. 49 indexed citations

Chu, Lin, Linda Chang, Lawrence F. Colwell, et al.. (2012). Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(12). 4133–4138. 21 indexed citations

Li, Rongcheng, Yanping Li, David Radley, et al.. (2012). Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine. 30(28). 4284–4291. 38 indexed citations

Bacon, Bruce R., Stuart C. Gordon, Eric Lawitz, et al.. (2011). Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. New England Journal of Medicine. 364(13). 1207–1217. 1229 indexed citations breakdown →

10.

Haupt, Richard M., Cosette M. Wheeler, Darron R. Brown, et al.. (2011). Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. International Journal of Cancer. 129(11). 2632–2642. 42 indexed citations

11.

Haupt, Richard M. & Heather L. Sings. (2011). The Efficacy and Safety of the Quadrivalent Human Papillomavirus 6/11/16/18 Vaccine Gardasil. Journal of Adolescent Health. 49(5). 467–475. 47 indexed citations

12.

Block, Stan L., Darron R. Brown, Archana Chatterjee, et al.. (2010). Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine. The Pediatric Infectious Disease Journal. 29(2). 95–101. 84 indexed citations

13.

Skjeldestad, Finn Egil, et al.. (2009). Incidence and Risk Factors for Genital Chlamydia trachomatis Infection: A 4-Year Prospective Cohort Study. Sexually Transmitted Diseases. 36(5). 273–279. 33 indexed citations

14.

Barr, Eliav, Christine K. Gause, Oliver Bautista, et al.. (2008). Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. American Journal of Obstetrics and Gynecology. 198(3). 261.e1–261.e11. 25 indexed citations

15.

Woelber, Linn, Karin Hellner, Friederike Gieseking, et al.. (2008). Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Archives of Gynecology and Obstetrics. 279(6). 803–807. 4 indexed citations

16.

Barr, Eliav & Heather L. Sings. (2008). Prophylactic HPV vaccines: New interventions for cancer control. Vaccine. 26(49). 6244–6257. 56 indexed citations

17.

Leodolter, Sepp, et al.. (2008). Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women – baseline data of a phase III vaccine trial. Wiener klinische Wochenschrift. 120(21-22). 666–671. 3 indexed citations

18.

Sings, Heather L., Jennifer Turpin, L. Joseph Su, et al.. (2007). Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstetricia Et Gynecologica Scandinavica. 87(1). 81–88. 34 indexed citations

19.

Garland, Suzanne M., Mauricio Hernández‐Ávila, Cosette M. Wheeler, et al.. (2007). Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine. 356(19). 1928–1943. 1353 indexed citations breakdown →

20.

Ault, Kevin A., et al.. (2005). Minimum serum antibody levels associated with protection from human papillomavirus 16 (HPV 16) reinfection among placebo subjects. Journal of Clinical Oncology. 23(16_suppl). 5024–5024. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact